<DOC>
	<DOCNO>NCT00144508</DOCNO>
	<brief_summary>To evaluate clinical efficacy tolerability MRA , patient RA randomize receive either MRA conventional DMARDs .</brief_summary>
	<brief_title>Phase III Comparative Study ( Open-Label ) MRA Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion criterion Diagnosed RA , basis criterion stipulate American Conference Rheumatism ( ACR ) 1987 . With RA continue least 6 month le 5 year , date first appearance take date RA diagnosis . Active RA despite least one DMARD immunosuppressant . Active disease define least 6 tender 6 swollen joint among 49 46 joint stipulate Japanese Rheumatism Foundation 's Drug Evaluation Committee ESR least 30 mm/hr CRP le 2.0mg/dL . Exclusion criterion Shown classIV Steinbrocker 's functional activity evaluation carry within 4 week administration study drug . Treated drug delay joint destruction ( infliximab , etanercept , leflunomide , etc . ) within 3 month administration study drug . The oral corticosteroid dose ( prednisolone equivalent 10 mg/day ) fix 2 week administration study drug . Subjected follow within 4 week administration study drug : ( ) Change dosage currently administer DMARDs and/or immunosuppressive agent . ( ii ) Plasma exchange method . ( iii ) Surgical treatment ( operation , etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>